Support Our Work

Please donate so we can continue our work to reduce the stigma of psychiatric illness, encourage research, and support educational activities for behavioral health professionals and the public. Ways you can donate and help are on our Support and Donations page. Thank you!

More Info

Latest News Around the Web

In Small Study, Adults With Binge-Eating Disorder Given Acute Naltrexone/Bupropion Appeared To Perform Better With Similar Maintenance Treatment Compared With Placebo

Healio (5/30, Herpen) reports, “Adults with binge-eating disorder who were given acute naltrexone/bupropion performed better with similar maintenance treatment compared with placebo,” investigators concluded in a 66-adult study that in which participants were “randomized 1:1 to receive either naltrexone/bupropion (n = 32) or placebo (n = 34) for 16 weeks.” The findings were presented at the American Society of Clinical Psychopharmacology annual meeting.

Related Links:

— “Naltrexone/bupropion maintenance therapy for binge-eating disorder superior to placebo “Robert Herpen, Healio, May 30, 2023

Many people losing Medicaid coverage amid redeterminations for procedural reasons

The New York Times (5/26, A1, Weiland) reported, “Hundreds of thousands of low-income Americans have lost Medicaid coverage in recent weeks as part of a sprawling unwinding of a pandemic-era policy that prohibited states from removing people from the program.” Early data indicate “many people lost coverage for procedural reasons, such as when Medicaid recipients did not return paperwork to verify their eligibility or could not be located. The large number of terminations on procedural grounds suggests that many people may be losing their coverage even though they are still qualified for it.” In addition, “many of those who have been dropped have been children.”

Related Links:

— “Hundreds of Thousands Have Lost Medicaid Coverage Since Pandemic Protections Expired “Noah Weiland, The New York Times, May 26, 2023

Ketamine May Be Promising Alternative To ECT For Patients With Difficult-To-Treat Depression Without Psychosis, Study Indicates

According to the New York Times (5/26, Caron), research “suggests that, for some patients, the anesthetic ketamine is a promising alternative to electroconvulsive therapy, or ECT, currently one of the quickest and most effective therapies for patients with difficult-to-treat depression.” In the “largest head-to-head comparison of the two treatments,” investigators “found that ketamine, when administered intravenously, was at least as effective as ECT in patients with treatment-resistant depression who do not have psychosis.” The findings were published online May 24 in the New England Journal of Medicine.

Psychiatric News (5/26) reported, “The participants receiving ECT reported greater problems with memory at the end of treatment compared with those who received ketamine, though by the one-month follow-up, there was little difference between the two groups,” the study revealed. Additionally, “ECT participants reported more musculoskeletal adverse effects, whereas ketamine participants reported more dissociation symptoms.”

HCPlive (5/27, Kunzmann) also covered the study.

Related Links:

— “Ketamine Shows Promise for Hard-to-Treat Depression in New Study “Christina Caron, The New York Times, May 26, 2023

High School-Aged Teens Experiencing Depression Or Suicidal Ideation Appear To Have Increased Perceived Access To Firearms Compared With Their Peers, Research Suggests

Healio (5/26, Weldon) reported, “High school-aged teens experiencing depression or suicidal ideation have increased perceived access to firearms compared with their peers,” which “is especially concerning, the researchers said, because easy firearm access increases the risk for suicide, which is the second leading cause of death among adolescents.” After examining data “from a web survey of 1,914 parent-teen duos between June 24, 2020, and July 22, 2020, to generate a nationally representative sample of U.S. teens,” investigators found that “teens with depression or suicidality were 56% more likely…to believe they had easy and quick access to a firearm either on their property or off it.” The findings were published online May 22 in the journal Pediatrics.

Related Links:

— “Teens with depression, suicidality have increased perceived access to firearms “Rose Weldon, Healio, May 26, 2023

Evidence Growing Of Marijuana’s Association With Psychiatric Disorders

According to NBC News (5/26, Syal), “evidence is growing of marijuana’s association with psychiatric disorders such as depression, bipolar disorder and schizophrenia, especially in young men.” A studypublished online May 4 in the journal Psychological Medicine has found “evidence of an association between cannabis use disorder and schizophrenia,” a finding “most striking in young men ages 21-30, but was also seen in women of the same age.” The study examined “data from almost seven million men and women in Denmark over the course of a few decades to look for a link between schizophrenia and cannabis use disorder.”

Related Links:

— “Marijuana linked to mental health risks in young adults, growing evidence shows ” Akshay Syal, NBC News, May 26, 2023

Foundation News

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.